Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vbi Vaccines Inc CS (NQ: VBIV )

0.5991 -0.0003 (-0.05%)
Streaming Delayed Price Updated: 11:08 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vbi Vaccines Inc CS

< Previous 1 2 3 Next >
VBI Vaccines Reports Full Year 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
From VBI Vaccines Inc.
Via Business Wire
VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports Third Quarter 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports Second Quarter 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines and Brii Biosciences Expand Hepatitis B Partnership To Address Both Prevention and Treatment in License and Collaboration Agreements for up to $437 Million Plus Royalties
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Results of Annual General Meeting
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces PreHevbri® is Now Available in the United Kingdom for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Poster Presentation at EASL 2023
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports First Quarter 2023 Financial Results
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Appoints Vaughn Himes to Board of Directors
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Reports Full Year 2022 Financial Results
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines to Discuss Progress in Hepatitis B Portfolio in Analyst-Led Fireside Chat
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Announces Health Canada Approval for PreHevbrio™ for the Prevention of Hepatitis B in Adults
From VBI Vaccines Inc.
Via Business Wire
CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal
From VBI Vaccines Inc.
Via Business Wire
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
From VBI Vaccines Inc.
Via Business Wire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.